Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Lupin Pharma Canada
Deal Size : Undisclosed
Deal Type : Agreement
Aytu BioPharma Partners with Lupin Canada For ADHD Drug Commercialization
Details : The agreement aims for the distribution and supply for Aytu's Adzenys XR-ODT and Cotempla XR-ODT product lines for the treatment of ADHD in Canada.
Product Name : Adzenys XR-ODT
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 10, 2024
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Lupin Pharma Canada
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.
Product Name : Cotempla
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
Details : AR101 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K and AKT pathways.
Product Name : AR101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2022
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Canaccord Genuity
Deal Size : $10.0 million
Deal Type : Public Offering
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering
Details : The Company intends to use the net proceeds from the Offering for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome (VEDS).
Product Name : AR101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 15, 2022
Lead Product(s) : Enzastaurin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Canaccord Genuity
Deal Size : $10.0 million
Deal Type : Public Offering
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XR-ODT is FDA-Approved as Bioequivalent to Adderall XR is the only FDA-approved, extended-release, orally-disintegrating tablet formulation of amphetamine,indicated for the treatment of ADHD in patients six years and older.
Product Name : Adzenys XR-ODT
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2022
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Acerus Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Divestment
Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma
Details : Acerus will acquire all remaining rights to Natesto in the United States from Aytu. Acerus will assume all product responsibilities associated with Natesto.
Product Name : Natesto
Product Type : Hormone
Upfront Cash : $7.5 million
January 04, 2021
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Acerus Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Divestment